IgD myeloma is a rare disorder with a very poor prognosis. An unusual case is reported where prolonged remission was obtained. Immunohistochemical staining of the bone marrow trephine biopsy
specimen proved invaluable in documenting early relapse. It is suggested that immunohistochemistry should be adopted more widely in view of the disparities evident in aspirates and trephines. Case report In 1980 a 46 year old white man presented with weight loss and back pain. IgDX myeloma was diagnosed, on the basis of a serum IgD paraprotein of 8 g/l, extensive lytic lesions on skeletal radiography, an infiltrate of 80% plasma cells in the bone marrow aspirate, a heavy infiltration of plasma cells in the bone marrow trephine biopsy specimen and normal renal function. He was treated initially with local radiotherapy and then had 18 courses of VMCP (vincristine 1 mg intravenously on day 1, melphalan 5 mg/M2 orally for four days, cyclophosphamide 100 mg/M2 orally for four days and prednisolone 60 mg/M2 orally for four days) over a two year period. The paraprotein became undetectable within a month of starting chemotherapy and a bone marrow aspirate at six months showed less than 1% plasma cells. He remained well with no evidence of paraproteinaemia for over 10 years and no change was noted in the skeletal survey. In 1992 he developed further back pain. Radiographs showed collapse of a previously noted lytic lesion in a lumbar vertebra. No paraprotein was detectable in serum or urine and blood counts were normal. A bone marrow aspirate showed 3% plasma cells.
The trephine biopsy specimen was processed using standard techniques. The haematoxylin and eosin stained trephine section was not diagnostic of myeloma. Consecutive sections of the trephine were stained using antisera to IgD, X, and K using the indirect immunoperoxidase system. group.bmj.com on March 31, 2017 -Published by http://jcp.bmj.com/ Downloaded from chains in his urine 02 g/24 hours. Further chemotherapy was given and his peripheral blood stem cells were harvested with a view to autologous transplantation. As his paraprotein and Bence-Jones protein have since both disappeared with the VMCP regimen, high dose treatment has not been given.
Discussion
Median survival in myeloma is 36 months,' and although about 2% of patients survive longer than 10 years, most of these long survivors never had advanced disease.2 IgD myeloma is rare, accounting for 1-2% of cases.3 It was first described in 19654; the median survival is 13-7 months.' It occurs in a younger age group than other types of myeloma and it has a male predominance.'
Our patient was unusual in that he did not have features typical of IgD myeloma, such as hepatomegaly, lymphadenopathy, extraosseous lesions, hypercalcaemia or renal failure. He also did not have Bence-Jones proteinuria, which is almost universal in IgD myeloma, until after his relapse. His prolonged survival after rapidly entering remission is also unusual as a rapid response to treatment is said to be a poor prognostic sign.5
The diagnostic criteria for myeloma usually include an assessment of numbers of plasma cells in the bone marrow aspirate.' However, in 48% of cases the aspirate will underestimate the degree of plasma cell infiltration.6
The disparity between the number of plasma cells in the aspirate and the trephine may reflect clumping of plasma cells. This disparity is worrying in view of the reliance many myeloma trials place on the number of plasma cells in the aspirate for diagnosis and trial entry. The simplicity of the immunohistochemical method and its value in this case suggest that it should be adopted more widely.
Finally, the prolonged survival of this patient emphasises that IgD myeloma need not always have a poor prognosis and argues well for more aggressive forms of treatment, currently under trial. The attainment of remission using a relatively non-aggressive protocol, as in this case, may prolong survival.
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Abstract
Teased fibre preparations are important in the investigation of peripheral nerve disorders, but can be a rather tedious procedure. A technique is described in which pretreatment of the nerve sample with collagenase before osmication substantially simplifies the actual teasing procedure. The 
